Year: 2024
Type: article
Abstract: In this issue of The FEBS Journal, we highlight a study by Madine et al. that explores a potential treatment strategy for light-chain amyloidosis, and a report by Shortt and colleagues investigating how immunomodulatory imide drugs can impact the cereblon interactome. We also feature work by Polikarpov and co-authors exploring how the enzyme BlEst2 could be the founding member of a previously unrecognised subgroup of carboxylesterases. Image created using Wordclouds.com.
Source: FEBS Journal
DOI: 10.1111/febs.17315
Author: Hajrah Khawaja
Institution: Federation of European Biochemical Societies
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4404302038